{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:57:38Z","timestamp":1794643058482,"version":"4.9.1"},"reference-count":129,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["RO1 DK 129564"],"award-info":[{"award-number":["RO1 DK 129564"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["BioRender.com\/s95i693"],"award-info":[{"award-number":["BioRender.com\/s95i693"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.xcrm.2024.101853","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T10:48:43Z","timestamp":1733741323000},"page":"101853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Metabolomics at the cutting edge of risk prediction of MASLD"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-5827","authenticated-orcid":false,"given":"En Ying","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Muthiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101853_bib1","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.3390\/jcm12196216","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective","volume":"12","author":"Eskridge","year":"2023","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.xcrm.2024.101853_bib2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.xcrm.2024.101853_bib3","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.xcrm.2024.101853_bib4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.xcrm.2024.101853_bib5","first-page":"691","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.xcrm.2024.101853_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14521","article-title":"A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications\u2014What the non-specialist needs to know","volume":"24","author":"Muthiah","year":"2022","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.xcrm.2024.101853_bib7","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.xcrm.2024.101853_bib8","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.xcrm.2024.101853_bib9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","article-title":"Past, present and future perspectives in nonalcoholic fatty liver disease","volume":"16","author":"Sanyal","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2024.101853_bib10","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.xcrm.2024.101853_bib11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1586\/egh.09.32","article-title":"Lipotoxicity in Nonalcoholic Fatty Liver Disease: Not All Lipids Are Created Equal","volume":"3","author":"Alkhouri","year":"2009","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2024.101853_bib12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nm0410-400","article-title":"Diacylglycerol-mediated insulin resistance","volume":"16","author":"Erion","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101853_bib13","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1021\/pr1002593","article-title":"Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease","volume":"9","author":"Barr","year":"2010","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.xcrm.2024.101853_bib14","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/hep.23229","article-title":"The plasma lipidomic signature of nonalcoholic steatohepatitis","volume":"50","author":"Puri","year":"2009","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.xcrm.2024.101853_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107127","article-title":"Large-scale metabolomic profiling and incident non-alcoholic fatty liver disease","volume":"26","author":"Gagnon","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.xcrm.2024.101853_bib16","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/hep.21763","article-title":"A lipidomic analysis of nonalcoholic fatty liver disease","volume":"46","author":"Puri","year":"2007","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.xcrm.2024.101853_bib17","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/s41467-020-15684-0","article-title":"Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance","volume":"11","author":"Roumans","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101853_bib18","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2024.101853_bib19","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3390\/cells11050844","article-title":"Molecular Mechanism of Lipotoxicity as an Interesting Aspect in the Development of Pathological States\u2014Current View of Knowledge","volume":"11","author":"Lipke","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.xcrm.2024.101853_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2023.101238","article-title":"Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances","volume":"91","author":"Musso","year":"2023","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.xcrm.2024.101853_bib21","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1073\/pnas.0334211100","article-title":"Differential effects of prostaglandin derived from \u03c9-6 and \u03c9-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion","volume":"100","author":"Bagga","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101853_bib22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00726-014-1894-9","article-title":"Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease","volume":"47","author":"Lake","year":"2015","journal-title":"Amino Acids"},{"key":"10.1016\/j.xcrm.2024.101853_bib23","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.metabol.2010.03.006","article-title":"Plasma metabolomic profile in nonalcoholic fatty liver disease","volume":"60","author":"Kalhan","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.xcrm.2024.101853_bib24","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1194\/jlr.M085613","article-title":"Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression","volume":"59","author":"Peng","year":"2018","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.xcrm.2024.101853_bib25","first-page":"7433","article-title":"A targeted metabolomic profiling of plasma acylcarnitines in nonalcoholic fatty liver disease","volume":"24","author":"Chang","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.xcrm.2024.101853_bib26","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1021\/pr201223p","article-title":"Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression","volume":"11","author":"Barr","year":"2012","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.xcrm.2024.101853_bib27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/metabo10040168","article-title":"Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach","volume":"10","author":"Ioannou","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.xcrm.2024.101853_bib28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12944-021-01526-5","article-title":"Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico","volume":"20","author":"Flores","year":"2021","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.xcrm.2024.101853_bib29","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1194\/jlr.P056002","article-title":"Biomarkers of NAFLD progression: a lipidomics approach to an epidemic","volume":"56","author":"Gorden","year":"2015","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.xcrm.2024.101853_bib30","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.cgh.2016.05.046","article-title":"Noninvasive Detection of Nonalcoholic Steatohepatitis Using Clinical Markers and Circulating Levels of Lipids and Metabolites","volume":"14","author":"Zhou","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.xcrm.2024.101853_bib31","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1007\/s00125-013-2981-2","article-title":"Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids","volume":"56","author":"Ore\u0161i\u010d","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.xcrm.2024.101853_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.997403","article-title":"Eicosanoids in inflammation in the blood and the vessel","volume":"13","author":"Yamaguchi","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xcrm.2024.101853_bib33","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12967-021-02820-7","article-title":"Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry","volume":"19","author":"Hu","year":"2021","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101853_bib34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1194\/jlr.P055640","article-title":"Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis1","volume":"56","author":"Loomba","year":"2015","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.xcrm.2024.101853_bib35","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1194\/jlr.M007096","article-title":"Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"51","author":"Feldstein","year":"2010","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.xcrm.2024.101853_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820923904","article-title":"Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis","volume":"13","author":"Caussy","year":"2020","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.xcrm.2024.101853_bib37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.bbalip.2016.06.020","article-title":"Oxidized cholesteryl esters and inflammation","volume":"1862","author":"Choi","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.xcrm.2024.101853_bib38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1530\/EJE-10-0299","article-title":"Cortisol, DHEA sulphate, their ratio, and all-cause and cause-specific mortality in the Vietnam Experience Study","volume":"163","author":"Phillips","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.xcrm.2024.101853_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114058","article-title":"Serum untargeted metabolomics delineates the metabolic status in different subtypes of non-alcoholic fatty liver disease","volume":"200","author":"Liu","year":"2021","journal-title":"J.\u00a0Pharm. Biomed. Anal."},{"key":"10.1016\/j.xcrm.2024.101853_bib40","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.2169\/internalmedicine.50.4682","article-title":"Serum dehydroepiandrosterone sulphate levels in patients with non-alcoholic fatty liver disease","volume":"50","author":"Koga","year":"2011","journal-title":"Intern. Med."},{"key":"10.1016\/j.xcrm.2024.101853_bib41","series-title":"Dehydroepiandrosterone in Nonalcoholic Fatty Liver Disease","author":"Sumida","year":"2012"},{"key":"10.1016\/j.xcrm.2024.101853_bib42","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/hep.22063","article-title":"Low Circulating Levels of Dehydroepiandrosterone in Histologically Advanced Nonalcoholic Fatty Liver Disease","volume":"47","author":"Charlton","year":"2008","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.xcrm.2024.101853_bib43","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1872-034X.2010.00704.x","article-title":"Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients","volume":"40","author":"Sumida","year":"2010","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.xcrm.2024.101853_bib44","doi-asserted-by":"crossref","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","article-title":"Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy","volume":"318","author":"Chiang","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.xcrm.2024.101853_bib45","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.xcrm.2024.101853_bib46","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.xcrm.2024.101853_bib47","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.xcrm.2024.101853_bib48","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/hep.32568","article-title":"Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD","volume":"76","author":"Smirnova","year":"2022","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.xcrm.2024.101853_bib49","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.xcrm.2024.101853_bib50","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.cmet.2023.07.011","article-title":"Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis","volume":"35","author":"Kuang","year":"2023","journal-title":"Cell Metabol."},{"key":"10.1016\/j.xcrm.2024.101853_bib51","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/oby.22627","article-title":"Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis","volume":"27","author":"Chen","year":"2019","journal-title":"Obes Silver Spring Md"},{"key":"10.1016\/j.xcrm.2024.101853_bib52","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/MEG.0b013e3282f4710a","article-title":"Bile acid levels are increased in the liver of patients with steatohepatitis","volume":"20","author":"Aranha","year":"2008","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2024.101853_bib53","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.taap.2013.01.022","article-title":"Decreased Hepatotoxic Bile Acid Composition and Altered Synthesis in Progressive Human Nonalcoholic Fatty Liver Disease","volume":"268","author":"Lake","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.xcrm.2024.101853_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1116861","article-title":"The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease","volume":"10","author":"Finney","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.xcrm.2024.101853_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.xcrm.2024.101853_bib56","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.cgh.2014.10.008","article-title":"Severity of Nonalcoholic Fatty Liver Disease and Progression to Cirrhosis Associate With Atherogenic Lipoprotein Profile","volume":"13","author":"Siddiqui","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.xcrm.2024.101853_bib57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12944-021-01573-y","article-title":"Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study","volume":"20","author":"Zou","year":"2021","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.xcrm.2024.101853_bib58","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2020.02.026","article-title":"Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor","volume":"299","author":"Konishi","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.xcrm.2024.101853_bib59","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1194\/jlr.P054387","article-title":"Lipoprotein subclass metabolism in nonalcoholic steatohepatitis","volume":"55","author":"M\u00e4nnist\u00f6","year":"2014","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.xcrm.2024.101853_bib60","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/livers2040020","article-title":"One Carbon Metabolism and S-Adenosylmethionine in Non-Alcoholic Fatty Liver Disease Pathogenesis and Subtypes","volume":"2","author":"Fern\u00e1ndez-Ramos","year":"2022","journal-title":"Liver"},{"key":"10.1016\/j.xcrm.2024.101853_bib61","doi-asserted-by":"crossref","first-page":"G77","DOI":"10.1152\/ajpgi.00301.2011","article-title":"Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis","volume":"302","author":"Kakisaka","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.xcrm.2024.101853_bib62","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1111\/liv.14174","article-title":"Total liver phosphatidylcholine content associates with non-alcoholic steatohepatitis and glycine N-methyltransferase expression","volume":"39","author":"M\u00e4nnist\u00f6","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.xcrm.2024.101853_bib63","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11306-021-01810-6","article-title":"Plasma and stool metabolomics to identify microbiota derived-biomarkers of metabolic dysfunction-associated fatty liver disease: effect of PNPLA3 genotype","volume":"17","author":"Mazzini","year":"2021","journal-title":"Metabolomics"},{"key":"10.1016\/j.xcrm.2024.101853_bib64","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.bbamem.2017.04.006","article-title":"The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease","volume":"1859","author":"van der Veen","year":"2017","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.xcrm.2024.101853_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010040","article-title":"Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover","volume":"21","author":"Simon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2024.101853_bib66","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jhep.2016.01.002","article-title":"Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease","volume":"64","author":"Luukkonen","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.xcrm.2024.101853_bib67","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.cmet.2014.08.002","article-title":"Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance","volume":"20","author":"Turpin","year":"2014","journal-title":"Cell Metabol."},{"key":"10.1016\/j.xcrm.2024.101853_bib68","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.3390\/ijms18122550","article-title":"Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Liver Lipidomics","volume":"18","author":"Li","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2024.101853_bib69","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1478-3231.2007.01475.x","article-title":"Sphingolipid signalling and liver diseases","volume":"27","author":"Mar\u00ed","year":"2007","journal-title":"Liver Int"},{"key":"10.1016\/j.xcrm.2024.101853_bib70","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12933-023-02049-2","article-title":"Plasma ceramides are associated with MRI-based liver fat content but not with noninvasive scores of liver fibrosis in patients with type 2 diabetes","volume":"22","author":"Denimal","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.xcrm.2024.101853_bib71","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2337\/dc17-1318","article-title":"Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis","volume":"41","author":"Apostolopoulou","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.xcrm.2024.101853_bib72","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001227","article-title":"Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients","volume":"7","author":"Mowry","year":"2021","journal-title":"Transplant. Direct"},{"key":"10.1016\/j.xcrm.2024.101853_bib73","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cca.2017.08.022","article-title":"Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis","volume":"473","author":"Qi","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.xcrm.2024.101853_bib74","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hep.29465","article-title":"Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance","volume":"67","author":"Gaggini","year":"2018","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.xcrm.2024.101853_bib75","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpeds.2016.01.026","article-title":"Amino acid metabolism is altered in adolescents with NAFLD - an untargeted, high resolution metabolomics study","volume":"172","author":"Jin","year":"2016","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.xcrm.2024.101853_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcmgh.2019.12.006","article-title":"Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression","volume":"10","author":"Du","year":"2020","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2024.101853_bib77","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/ejcn.2017.43","article-title":"Serum metabolomic profiling highlights pathways associated with liver fat content in a general population sample","volume":"71","author":"Koch","year":"2017","journal-title":"Eur. J. Clin. Nutr."},{"key":"10.1016\/j.xcrm.2024.101853_bib78","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/hep.23639","article-title":"Fatty liver and fibrosis in glycine N-methyltransferase knockout mice is prevented by nicotinamide","volume":"52","author":"Varela-Rey","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.xcrm.2024.101853_bib79","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ymgme.2017.02.010","article-title":"Cystathionine beta-synthase deficiency alters hepatic phospholipid and choline metabolism: Post-translational repression of phosphatidylethanolamine N-methyltransferase is a consequence rather than a cause of liver injury in homocystinuria","volume":"120","author":"Jacobs","year":"2017","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.xcrm.2024.101853_bib80","doi-asserted-by":"crossref","first-page":"36258","DOI":"10.1074\/jbc.M111.265348","article-title":"Deletion of betaine-homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas","volume":"286","author":"Teng","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2024.101853_bib81","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/hmg\/10.5.433","article-title":"Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition","volume":"10","author":"Chen","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2024.101853_bib82","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1053\/j.gastro.2017.01.015","article-title":"Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis","volume":"152","author":"Alonso","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xcrm.2024.101853_bib83","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/oby.22667","article-title":"Association of Hepatic Global DNA Methylation and Serum One-Carbon Metabolites with Histological Severity in Patients with NAFLD","volume":"28","author":"Lai","year":"2020","journal-title":"Obes Silver Spring Md"},{"key":"10.1016\/j.xcrm.2024.101853_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11119","article-title":"Deciphering the role of aberrant DNA methylation in NAFLD and NASH","volume":"8","author":"Vachher","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.xcrm.2024.101853_bib85","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/liv.13249","article-title":"Nonalcoholic steatohepatitis is associated with a state of betaine-insufficiency","volume":"37","author":"Sookoian","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.xcrm.2024.101853_bib86","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/CS20110060","article-title":"Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine","volume":"121","author":"Kalhan","year":"2011","journal-title":"Clin. Sci."},{"key":"10.1016\/j.xcrm.2024.101853_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.702826","article-title":"Branched-chain Amino Acids: Catabolism in Skeletal Muscle and Implications for Muscle and Whole-body Metabolism","volume":"12","author":"Mann","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.xcrm.2024.101853_bib88","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00726-010-0679-z","article-title":"Acute hyperammonemia activates branched-chain amino acid catabolism and decreases their extracellular concentrations: different sensitivity of red and white muscle","volume":"40","author":"Holecek","year":"2011","journal-title":"Amino Acids"},{"key":"10.1016\/j.xcrm.2024.101853_bib89","doi-asserted-by":"crossref","first-page":"47","DOI":"10.21037\/tgh.2018.07.06","article-title":"Branched-chain amino acids in liver diseases","volume":"3","author":"Tajiri","year":"2018","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2024.101853_bib90","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/nu9070642","article-title":"A Branched-Chain Amino Acid-Related Metabolic Signature Characterizes Obese Adolescents with Non-Alcoholic Fatty Liver Disease","volume":"9","author":"Goffredo","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.xcrm.2024.101853_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138889","article-title":"Adipose Tissue Dysfunction and Altered Systemic Amino Acid Metabolism Are Associated with Non-Alcoholic Fatty Liver Disease","volume":"10","author":"Cheng","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2024.101853_bib92","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.numecd.2016.03.013","article-title":"Branched-chain and aromatic amino acids, insulin resistance and liver specific ectopic fat storage in overweight to obese subjects","volume":"26","author":"Haufe","year":"2016","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"key":"10.1016\/j.xcrm.2024.101853_bib93","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/liv.14743","article-title":"Serum aromatic and branched-chain amino acids associated with NASH demonstrate divergent associations with serum lipids","volume":"41","author":"de Mello","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.xcrm.2024.101853_bib94","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3390\/biomedicines10061444","article-title":"The Emerging Role of Branched-Chain Amino Acids in Liver Diseases","volume":"10","author":"Lo","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.xcrm.2024.101853_bib95","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature24661","article-title":"A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites","volume":"551","author":"Dodd","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101853_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2024.109581","article-title":"Molecular mechanism and therapeutic significance of essential amino acids in metabolically associated fatty liver disease","volume":"126","author":"Deng","year":"2024","journal-title":"J.\u00a0Nutr. Biochem."},{"key":"10.1016\/j.xcrm.2024.101853_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121626","article-title":"A metabolomics approach to the validation of predictive metabolites and phenotypic expression in non-alcoholic fatty liver disease","volume":"322","author":"Ganesan","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.xcrm.2024.101853_bib98","article-title":"Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2024.101853_bib99","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nm.3145","article-title":"Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis","volume":"19","author":"Koeth","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101853_bib100","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.3390\/biomedicines9101346","article-title":"Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges","volume":"9","author":"Kuchay","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.xcrm.2024.101853_bib101","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ajg.2016.318","article-title":"Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver","volume":"112","author":"Feldman","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.xcrm.2024.101853_bib102","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1038\/s41598-017-05040-6","article-title":"Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice","volume":"7","author":"Tu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2024.101853_bib103","doi-asserted-by":"crossref","first-page":"312","DOI":"10.2337\/db13-0774","article-title":"Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity","volume":"63","author":"Hyysalo","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.xcrm.2024.101853_bib104","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s43042-023-00433-x","article-title":"Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity","volume":"24","author":"Samarasinghe","year":"2023","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"10.1016\/j.xcrm.2024.101853_bib105","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127902","article-title":"Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids","volume":"4","author":"Luukkonen","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2024.101853_bib106","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xcrm.2024.101853_bib107","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/gutjnl-2020-320646","article-title":"LPIAT1\/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover","volume":"70","author":"Tanaka","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.xcrm.2024.101853_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102658","article-title":"Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes","volume":"52","author":"Meroni","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.xcrm.2024.101853_bib109","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.49882","article-title":"Obesity-linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease","volume":"8","author":"Helsley","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.xcrm.2024.101853_bib110","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132158","article-title":"Hydroxysteroid 17-\u03b2 dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease","volume":"5","author":"Luukkonen","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2024.101853_bib111","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217543120","article-title":"Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis","volume":"120","author":"Luukkonen","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101853_bib112","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1038\/s41591-023-02539-6","article-title":"Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101853_bib113","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/HEP.0000000000000542","article-title":"Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)","volume":"79","author":"Noureddin","year":"2024","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.xcrm.2024.101853_bib114","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/dom.13285","article-title":"Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus","volume":"20","author":"Bril","year":"2018","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.xcrm.2024.101853_bib115","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/hep4.1188","article-title":"Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.xcrm.2024.101853_bib116","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1177\/2050640618804444","article-title":"Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease","volume":"6","author":"Rau","year":"2018","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.xcrm.2024.101853_bib117","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/metabo12060514","article-title":"Interactions between Tryptophan Metabolism, the Gut Microbiome and the Immune System as Potential Drivers of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Diseases","volume":"12","author":"Teunis","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.xcrm.2024.101853_bib118","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.3748\/wjg.v23.i15.2771","article-title":"Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease","volume":"23","author":"Dong","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.xcrm.2024.101853_bib119","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/apt.15710","article-title":"Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome","volume":"51","author":"Moolla","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.xcrm.2024.101853_bib120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/ijmr.IJMR_1456_17","article-title":"Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern","volume":"149","author":"Dhamija","year":"2019","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.xcrm.2024.101853_bib121","article-title":"Metabolomics in hepatocellular carcinoma: From biomarker discovery to precision medicine","volume":"4","author":"Wu","year":"2022","journal-title":"Front. Med. Technol."},{"key":"10.1016\/j.xcrm.2024.101853_bib122","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M111.010694","article-title":"Metabolomics Study of Stepwise Hepatocarcinogenesis From the Model Rats to Patients: Potential Biomarkers Effective for Small Hepatocellular Carcinoma Diagnosis","volume":"11","author":"Tan","year":"2012","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.xcrm.2024.101853_bib123","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1158\/1940-6207.CAPR-17-0249","article-title":"Metabolomics Profiles of Hepatocellular Carcinoma in a Korean Prospective Cohort: The Korean Cancer Prevention Study-II","volume":"11","author":"Jee","year":"2018","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.xcrm.2024.101853_bib124","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/ijms24010210","article-title":"Metabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis","volume":"24","author":"Ahmed","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2024.101853_bib125","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/hep.25778","article-title":"Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: New evidence on the potential therapeutic mechanism","volume":"56","author":"Zein","year":"2012","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.xcrm.2024.101853_bib126","article-title":"Changes of the Fatty Acid Profile in Erythrocyte Membranes of Patients following 6-Month Dietary Intervention Aimed at the Regression of Nonalcoholic Fatty Liver Disease (NAFLD)","volume":"2018","author":"Maciejewska","year":"2018","journal-title":"Chin. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2024.101853_bib127","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.1038\/s41598-022-10481-9","article-title":"Effects of exercise on NAFLD using non-targeted metabolomics in adipose tissue, plasma, urine, and stool","volume":"12","author":"Babu","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2024.101853_bib128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044106","article-title":"Metabolomic Profiling to Identify Predictors of Response to Vitamin E for Non-Alcoholic Steatohepatitis (NASH)","volume":"7","author":"Cheng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2024.101853_bib129","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1136\/gutjnl-2018-317584","article-title":"Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease","volume":"68","author":"Caussy","year":"2019","journal-title":"Gut"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124006244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124006244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T21:31:32Z","timestamp":1737408692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124006244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":129,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2666379124006244"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101853","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolomics at the cutting edge of risk prediction of MASLD","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101853","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101853"}}